Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 25498909 | HLA (HLA) | hemophilia a | NA | NA | NA | positive | |
| moreover, studies with an hla-transgenic, fviii-deficient mouse model demonstrated that antibody production from fviii-primed spleen cells in vitro were profoundly inhibited in the presence of these fviii-specific tregs, suggesting potential utility to treat anti-fviii inhibitory antibody formation in hemophilia a patients. | |||||||
| 27471234 | HLA (HLA) | hemophilia a | NA | NA | NA | unclassified | |
| t cells from hemophilia a subjects recognize the same hla-restricted fviii epitope with a narrow tcr repertoire. | |||||||
| 29025906 | NA (NA) | hemophilia a | NA | NA | NA | positive | |
| interestingly, this peptide was found to have a higher predicted affinity for hla-dq than for hla-dr. taken together, our data suggest that hla-dq participates in the presentation of factor viii peptides, thereby contributing to the development of inhibitory antibodies in a proportion of patients with severe hemophilia a. | |||||||
| 29025906 | HLA-DR (HLA-DR) | hemophilia a | NA | NA | NA | positive | |
| interestingly, this peptide was found to have a higher predicted affinity for hla-dq than for hla-dr. taken together, our data suggest that hla-dq participates in the presentation of factor viii peptides, thereby contributing to the development of inhibitory antibodies in a proportion of patients with severe hemophilia a. | |||||||
| 29766236 | HLA (HLA) | hemophilia a | Korean | NA | NA | unclassified | |
| ethnicity-specific impact of hla i/ii genotypes on the risk of inhibitor development: data from korean patients with severe hemophilia a. inhibitor development is the most serious complication in patients with hemophilia. | |||||||
| 29766236 | HLA (HLA) | hemophilia a | Korean | NA | NA | only_studied | |
| we investigated association of hla genotypes with inhibitor development in korean patients with severe hemophilia a (ha). | |||||||
| 30037801 | HLA-DRB1 (HLA-DRB1) | hemophilia a | NA | NA | NA | unclassified | |
| hla-drb1-factor viii binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study. | |||||||
| 30037801 | MHC (MHC) | hemophilia a | NA | NA | NA | unclassified | |
| development of anti-factor viii (fviii) inhibitory antibodies (inhibitors) is the most significant treatment complication of hemophilia a. characteristics of the interaction between major histocompatibility complex (mhc) class ii and fviii peptides may influence fviii antigen presentation to t cells and subsequent inhibitor development. | |||||||
| 30037801 | HLA-DRB1 (HLA-DRB1) | hemophilia a | NA | NA | NA | negation | |
| we analyzed predicted hla-drb1, a subset of mhc class ii, and fviii peptide binding and its association with inhibitor development among subjects with nonsevere hemophilia a, including 20 cases (inhibitor titer >= 1.0 bu/ml on 2 occasions or on 1 occasion with subsequent immune tolerance induction) and 37 controls (who had received fviii infusions and did not develop inhibitor). | |||||||
| 30266735 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | hemophilia a | NA | NA | NA | unclassified | |
| our results emphasize the importance of knowing both the f8 missense mutation and the human leukocyte antigen alleles of a patient with missense mutation hemophilia a if his underlying risk of inhibitor development is to be estimated. | |||||||
Copyright 2024